Compare AbCellera Biologics Inc (ABCL) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs JetBlue Airways Corporation — how do they compare? AbCellera Biologics Inc trades at $9.02 (market cap $2.85B), while JetBlue Airways Corporation trades at $5.81 (market cap $2.13B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| ABCL | JBLU | |
|---|---|---|
Market Cap | $2.85B | $2.13B |
Sector | Health | Industrials |
52-Week High | $9.76 | $6.46 |
52-Week Low | $2.78 | $4.03 |
Enterprise Value | $2.45B | $9.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
JetBlue (JBLU) trades at $6.07, down 1.94% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a Q2 2026 earnings beat but continues to post net losses, with negative profit margins and declining revenue trends. Recent news includes analyst downgrades from Citigroup citing geopolitical risks, though the company has introduced new fare structures and lounge enhancements to drive growth.
The outlook remains challenging with persistent losses and high debt levels, though cost management and strategic initiatives offer potential upside. Key risks include fuel cost volatility, competitive pressures, and execution of the 2028 profit target. Analyst consensus is cautious with a $5.18 price target below current levels, reflecting skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
